The use of CDK4/6 inhibitors in combination with aromatase inhibitors or fulvestrant has fundamentally changed the treatment of ET resistance in hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer [6,7,8]. This evidence concerns the gene CYP19A1 and breast carcinoma.